Developer acquires global rights to Parkinson’s drug in deal worth $300M
In a deal that could be worth more than $300 million, a Korean biotech has acquired exclusive global rights to develop and commercialize 1ST Biotherapeutics‘ 1ST-104, an oral treatment candidate…